𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterizing Melphalan Efficacy and Toxicity in Multiple Myeloma Patients with Renal Insufficiency

✍ Scribed by Patel, Seema; Culos, Kathryn; Sweiss, Karen; Paul, Shilpa; Patel, Pritesh Rajni; Rondelli, Damiano

Book ID
122233127
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
51 KB
Volume
20
Category
Article
ISSN
1083-8791

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Renal function in the elimination of ora
Renal function in the elimination of oral melphalan in patients with multiple myeloma
✍ C. G. Adair; J. M. Bridges; Z. R. Desai πŸ“‚ Article πŸ“… 1986 πŸ› Springer 🌐 English βš– 329 KB

Pharmacokinetic studies in 11 patients with multiple myeloma were undertaken on the first and last days of one course of chemotherapy. The drug was administered PO in single doses of 6-14 mg daily. Melphalan concentrations were determined by high-performance liquid chromatography. The interpatient v

VAD chemotherapyβ€”toxicity and efficacyβ€”i
VAD chemotherapyβ€”toxicity and efficacyβ€”in patients with multiple myeloma and other lymphoid malignancies
✍ Dr H. Anderson; J. H. Scarffe; M. Lambert; D. B. Smith; C. C. Chan; G. Chadwick; πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 529 KB

Thirty-three patients with multiple myeloma (11 untreated, 15 refractory and seven relapsed patients) have received vincristine and adriamycin infusion therapy with oral dexamethasone (VAD). The median number of course received was five. In addition 16 patients with lymphoid malignancy have received